NSPR stock forecast, quote, news & analysis
InspireMD Inc is a United States-based medical device company... Show more
InspireMD (NSPR) Stock Analysis: FDA Decisions and TCAR Expansion Shape the Path Ahead
Key Takeaways
- InspireMD (NSPR) is a medical device company developing the CGuard Prime carotid stent system for stroke prevention, built on its proprietary MicroNet mesh technology.
- Over the trailing 30 days, NSPR has moved only about 1% higher versus its closing price from 30 days earlier, following a period of elevated volatility.
- The primary near-term catalyst is regulatory: the company anticipates a U.S. FDA decision on its CGuard Prime 80 cm system for transcarotid artery revascularization (TCAR) in the fourth quarter of 2026.
- Second-quarter 2026 revenue was roughly flat year over year, with 21% international growth offsetting the impact of a voluntary U.S. recall of the CGuard Prime 135 cm delivery system.
- The company implemented an approximately 20% workforce reduction expected to generate about $9 million in annualized cost savings.
- For additional detail, explore InspireMD's Price Targets, Earnings, and Forecast pages.
- To discover AI-driven trading strategies, visit Tickeron's Trending AI Robots.
Current Market Snapshot
InspireMD shares have traded in a notably wide range over the past year, with a 52-week span of roughly $0.63 to $2.57, and the stock has spent recent weeks near the lower end of that band. Over the trailing 30 days, the net move has been modest, roughly 1% higher versus the closing level from a month earlier, even as intraday swings have been pronounced. This pattern reflects a small-cap medical device company whose near-term share price remains heavily influenced by regulatory milestones and funding developments rather than steady earnings growth. Broader sentiment toward micro-cap and small-cap healthcare names has also contributed to the choppy trading environment, keeping investors focused on discrete catalysts.
InspireMD (NSPR) Business Overview and Competitive Position
InspireMD is a Miami-based medical device company focused on the treatment of carotid artery disease and the prevention of stroke. Its core technology, MicroNet, is a micron-scale mesh sleeve wrapped over a stent to provide embolic protection during stenting procedures. The company's flagship CGuard platform combines this mesh with a self-expanding nitinol stent in a single device. InspireMD markets the system internationally and has been working to reestablish its U.S. presence, while advancing the CGuard Prime 80 cm variant designed specifically for TCAR procedures. The company estimates that more than 35,000 TCAR procedures are performed annually in the United States, which it frames as a potential doubling of its domestic addressable market. Investors follow NSPR for its stroke-prevention franchise, its clinical data, and its pipeline, which includes the SwitchGuard neuroprotection system currently in a Phase 3 study.
Recent Developments Driving NSPR
The past several months have been defined by a voluntary U.S. recall of the CGuard Prime 135 cm delivery system, announced after technical performance issues were identified during the controlled launch. The action paused U.S. commercialization and weighed on reported results: second-quarter revenue was about $1.8 million, essentially flat year over year, as 21% international growth was offset by recall-related customer credits and an inventory impairment. Net loss widened to $14.3 million in the quarter. In response, the company implemented a roughly 20% workforce reduction and expects about $9 million in annualized savings. On the funding front, InspireMD amended certain Series J and Series K warrants in September 2026, a move that could provide up to $11 million in gross proceeds while aligning exercise terms with the anticipated FDA approval of CGuard Prime 80 cm. Meanwhile, clinical progress has continued: in the CGUARDIANS II pivotal study, the CGuard Prime 80 cm system demonstrated 100% acute device success with no major adverse events at 30 days in the first 36 patients evaluated.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots that trade across thousands of tickers, only the top-performing and most relevant strategies appear in this section. The robots vary by trading style, timeframe, and performance metrics, giving users a way to compare approaches that range from short-term momentum to longer-horizon signals. The page is designed to help traders identify active, data-driven strategies without offering personalized investment recommendations. Those interested in automated, algorithm-based trading tools can explore the current lineup on the Trending AI Robots page.
2026 Outlook and What Investors Should Watch
InspireMD's trajectory through the remainder of 2026 hinges primarily on regulatory outcomes. Investors are monitoring an expected FDA decision on the CGuard Prime 80 cm system for TCAR in the fourth quarter, as well as the status of the redesigned CGuard Prime 135 cm delivery system and the original CGuard platform. Clinical enrollment progress in the CGUARDIANS III trial for SwitchGuard will also be closely watched. Beyond approvals, the company's cash position, the ability to convert warrant-related proceeds into working capital, and the pace of any U.S. market relaunch will shape the outlook. Execution risk around manufacturing, reimbursement, and competitive dynamics in carotid stenting remains relevant, and the company continues to operate with a history of net losses. These are the factual drivers most likely to influence the stock in the near to medium term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NSPR in upward trend: price rose above 50-day moving average on November 06, 2026
NSPR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 51 of 61 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NSPR as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for NSPR just turned positive on October 23, 2026. Looking at past instances where NSPR's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
Following a +11.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where NSPR advanced for three days, in 152 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for NSPR moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 18 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NSPR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NSPR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.035) is normal, around the industry mean (4.142). P/E Ratio (-1.141) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.767) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. NSPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical devices
Industry MedicalNursingServices